Análisis de un protocolo de radioterapia guiada por imagen con marcadores fiduciales en radioterapia prostática hipofraccionada

  1. Roser Fayos-Solá Capilla 1
  2. Pablo Castro Tejero 1
  3. Almudena Zapatero Laborda 1
  4. David Hernández González 1
  5. María Roch González 1
  6. Alberto Viñals Muñoz 1
  7. Paloma Botella Faus 1
  1. 1 Hospital Universitario La Princesa, Madrid
Journal:
Revista de Física Médica

ISSN: 1576-6632

Year of publication: 2023

Volume: 24

Issue: 1

Pages: 43-50

Type: Article

DOI: 10.37004/SEFM/2023.24.1.003 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista de Física Médica

Sustainable development goals

Abstract

The main objective of this work is to evaluate the validity of the Image-Guided Radiation Therapy (IGRT) protocol implemented in cases of prostate cancer with implantation of fiducial markers, as well as to determine the magnitude of intrafractional displacements during the first five sessions of a group of 32 patients treated throughout one year. Two weeks prior to the CT adquisition, the patient is implanted with a set of minimum 3 intraprostatic gold fiducial markers. During the treatment, with the combined use of the Auto Beam Hold (ABH) system and the acquisition of paired kV-MV images, we can assess the correct positioning of both: the area to be treated, and the patient. From the results obtained, we found that certain patients accumulate most of the beam interruptions, which indicate us which ones had problems in the positioning from the beginning, and allows us to evaluate the possible extension of the monitoring in certain cases. The results of the displacements indicate that corrections lower than 5 mm are required in all cases. The use of the Image-Guided Radiation Therapy (IGRT) protocols in cases of variable anatomies represents an improvement in the correct positioning of the patient and, consequently in the treatment administration.

Bibliographic References

  • WHO report on cancer: setting priorities, investing wisely and providing care for all. Geneva: World Health Organization; 2020.
  • Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89.
  • Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int. 2002 Jul;90(2):162-73. doi: 10.1046/j.1464-410x.2002.2822.x. PMID: 12081758.
  • Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.
  • Ian Thompson, James Brantley Thrasher, et al. Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update.
  • Hanks GE, Martz KL, Diamond JJ (1988). The effect of dose on local control of prostate cancer.Int J RadiatOncolBiolPhys 15:1299-1305.
  • Ghilezan MJ, Jaffray DA, Siewerdsen JH, Van Herk M, Shetty A, Sharpe MB, Zafar Jafri S, Vicini FA, Matter RC, Brabbins DS, Martinez AA. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):406-17. doi: 10.1016/j.ijrobp.2003.10.017. PMID: 15890582.
  • Crook JM, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol. 1995 Oct;37(1):35-42. doi: 10.1016/0167-8140(95)01613-l. PMID: 8539455.
  • Dang A, Kupelian PA, Cao M, Agazaryan N, Kishan AU. Image-guided radiotherapy for prostate cancer. Transl Androl Urol. 2018 Jun;7(3):308-320. doi: 10.21037/tau.2017.12.37. PMID: 30050792; PMCID: PMC6043755.
  • Zapatero A, Roch M, Büchser D, Castro P, Fernández-Banda L, Pozo G, Liñán O, Martin de Vidales C, Cruz-Conde A, García-Vicente F. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. Clin Transl Oncol. 2017 Sep;19(9):1161-1167. doi: 10.1007/s12094-017-1655-9. Epub 2017 Apr 3. PMID: 28374321.
  • Roch M, Zapatero A, Castro P, Büchser D, Pérez L, Hernández D, Ansón C, Chevalier M, García-Vicente F. Impact of rectum and bladder anatomy in intrafractional prostate motion during hypofractionated radiation therapy. Clin Transl Oncol. 2019 May;21(5):607-614. doi: 10.1007/s12094-018-1960-y. Epub 2018 Oct 17. PMID: 30328558.
  • Rosario T, van der Weide L, Admiraal M, Piet M, Slotman B, Cuijpers J. Toward planning target volume margin reduction for the prostate using intrafraction motion correction with online kV imaging and automatic detection of implanted gold seeds. Pract Radiat Oncol. 2018 Nov-Dec;8(6):422-428. doi: 10.1016/j.prro.2018.04.008. Epub 2018 Apr 25. PMID: 29907506.
  • Korpics MC, Rokni M, Degnan M, Aydogan B, Liauw SL, Redler G. Utilizing the TrueBeam Advanced Imaging Package to monitor intrafraction motion with periodic kV imaging and automatic marker detection during VMAT prostate treatments. J Appl Clin Med Phys. 2020 Mar;21(3):184-191. doi: 10.1002/acm2.12822. Epub 2020 Jan 24. PMID: 31981305; PMCID: PMC7075383.
  • Varian system. TrueBeam Instrucciones de uso. Junio 2018
  • Castro, P. , Roch, M. , Zapatero, A. , Büchser, D. , Garayoa, J. , Ansón, C. , Hernández, D. , Huerga, C. , Chevalier, M. , González, S. and Pérez, L. (2018) Multicomponent Assessment of the Geometrical Uncertainty and Consequent Margins in Prostate Cancer Radiotherapy Treatment Using Fiducial Markers. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 7, 503-521. doi: 10.4236/ijmpcero.2018.74043.
  • Tanyi JA, He T, Summers PA, Mburu RG, Kato CM, Rhodes SM, Hung AY, Fuss M. Assessment of planning target volume margins for intensity-modulated radiotherapy of the prostate gland: role of daily inter- and intrafraction motion. Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1579-85. doi: 10.1016/j.ijrobp.2010.02.001. Epub 2010 May 14. PMID: 20472357.
  • Pouliot J, Aubin M, Langen KM, et al. (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys 2003;56:862–866
Data source: Dialnet